AAN Guidelines: Cannabis Extract Effective for MS Spasticity Symptoms and Pain | Research

The takeaway

The American Academy of Neurology gave its highest recommendation (Level A) for oral cannabis extract for MS spasticity symptoms and pain, while noting it is probably ineffective for objective spasticity measures.

Read this if you have MS and want to know what the neurological evidence says about cannabis treatments.

Level A recommendation: oral cannabis extract effective for MS spasticity symptoms and pain

What the researchers found

The AAN's comprehensive evidence-based guidelines issued Level A recommendations (strongest) that oral cannabis extract is effective short-term for spasticity-related symptoms and pain (excluding central neuropathic pain), and that ginkgo biloba is ineffective for cognitive improvement in MS.

Level B recommendations (probable) included: THC is probably effective for spasticity symptoms and pain but probably ineffective for objective spasticity or tremor. Sativex (nabiximols) is probably effective for spasticity symptoms, pain, and urinary frequency but probably ineffective for objective spasticity and bladder incontinence.

The guidelines emphasized significant concern about CNS-related adverse effects and noted that in the U.S., a lack of standardized, FDA-regulated preparations limits the practical application of these findings.

Why it matters

This represents the first major neurology professional organization to give its highest evidence grade (Level A) to a cannabis-based treatment. The distinction between subjective symptom improvement and objective measurement improvement is clinically important and well-articulated.

The numbers in context

Level A: oral cannabis extract for spasticity symptoms and pain. Level B: THC for spasticity symptoms/pain; Sativex for spasticity symptoms/pain/urinary frequency; magnetic therapy for fatigue. Level B (ineffective): all cannabinoids for objective spasticity; fish oil for relapses/disability.

How the study worked

This is a commentary on the AAN evidence-based practice guidelines published in March 2014. The guideline panel reviewed and classified articles according to the AAN therapeutic scheme, with recommendations linked to evidence strength.

What this study cannot tell us

The commentary notes that U.S. availability of standardized cannabis preparations is limited. The guidelines cover evidence through September 2013 and may not reflect more recent data. The distinction between subjective and objective outcomes complicates implementation.

How to read the evidence

This is a commentary on systematic evidence-based guidelines from a major medical professional organization, representing the highest tier of evidence synthesis.

When this study was published

Published in 2014. The AAN guidelines have been influential in clinical practice and subsequent research.

The bigger picture

The AAN guidelines represent a significant institutional endorsement of cannabis-based treatments for specific MS indications. The careful distinction between subjective symptom relief (effective) and objective measures (ineffective) helps clinicians set appropriate expectations.

Questions still open

Will FDA regulation of cannabis preparations improve access in the U.S.? Do the subjective benefits translate to meaningful functional improvements? Should guidelines prioritize subjective patient-reported outcomes differently?

Common questions

What does Level A mean?

In AAN terminology, Level A is the highest recommendation, meaning the evidence is strong enough that clinicians should offer this treatment. It is based on multiple high-quality studies showing consistent benefit.

Why is cannabis effective for symptoms but not objective spasticity?

Spasticity has both a subjective component (how stiff and uncomfortable patients feel) and an objective component (measurable muscle tone on examination). Cannabis appears to reduce the subjective experience of spasticity and associated pain without significantly changing the measurable muscle tone.

Read the original research

Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary.

Clinical therapeutics, 36(12), 1972-1978

View on PubMed ↗Publisher’s paper ↗

Citation

Yadav, Vijayshree; Narayanaswami, Pushpa. (2014). Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary.. Clinical therapeutics, 36(12), 1972-1978. https://doi.org/10.1016/j.clinthera.2014.10.011